Deborah Charych

Scientific Advisory Board Member

Dr. Deborah Charych has held scientific leadership positions in both academia and biotech. At Nektar Therapeutics, she led the strategic development of the Immuno-Oncology pipeline and designed NKTR-214, an IL-2 receptor agonist, currently in Phase 3. Alternative engineering of the IL-2 pathway led to clinical development of NKTR-358 for autoimm...

Roles at Xilio Therapeutics

  • Scientific Advisory Board Member

    Current role

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.